Company profile

Avrion Therapeutics AG

Switzerland Innovation Park Basel Area
Gewerbestrasse 24
4123 Allschwil
Switzerland
Gene therapy
Neurodegenerative disorders
ALS
Biotech

Founded in 2020, based on 10+ years of research at the Swiss Federal Institute of Technology EPFL Brain Mind Institute and Bertarelli Foundation Gene Therapy Platform, Avrion Therapeutics targets genetically-linked neurodegenerative diseases using precision gene therapy to enable long-term solutions. Avrion has developed a first-in-class precision gene therapy platform to selectively and safely target discrete cells in the brain including neurons and astrocytes. This therapeutic platform is supported by a preclinical discovery engine to identify novel targets to treat neurodegenerative diseases with unmet medical need. Avrions’ first clinical candidate gene therapy product: AVR-001

Contact

Maximilien Murone
Maximilien Murone
CEO

SWISS Pavilion participations (starting 2019)

Share

Official program